The significance of NLRP3 activation in ovarian cancer is further confirmed by a study by Li et al. [226], where they found that NLRP3 is overexpressed in ovarian cancer and is correlated with the poor survival rate and cisplatin resistance to ovarian cancer. Here, NLRP3 is linked to ovarian carcinoma.